Clinical trials: Mild to Moderate COVID-19
COVID-19
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
The purpose of this study is to learn about the side effects (safety) of the study medicine PF-07321332 (nirmatrelvir)/ritonavir for the treatment of mild to moderate COVID-19 infection in adults with severe renal impairment.
- Trial name
- NCT05487040
- Testing
- PF-07321332 (nirmatrelvir)/ritonavir
- Where
- 52 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Covid19
Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19
TB006, a monoclonal antibody, is an anti-inflammatory and anti-fibrotic agent that reduces the severity of underlying diseases in COVID-19 patients.
- Trial name
- NCT04801056
- Testing
- TB006
- Sponsor
- TrueBinding, Inc.
COVID-19
Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19
AD17002 enhances nasal mucosal innate immunity and has met safety and efficacy endpoints in studies of nasal adjuvants or intranasal immunomodulators.
- Trial name
- NCT05541510
- Testing
- AD17002 + Formulation buffer
- Where
- 3 sites in Indonesia
- Volunteers
- 180 people
- Sponsor
- Advagene Biopharma Co. Ltd.
COVID-19
Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients
This study is a multi-center, single-arm, open-label, pilot clinical trial to explore efficacy and safety of Pyramax in mild to moderate COVID-19 patients
- Trial name
- NCT05633420
- Testing
- Pyramax
- Where
- 2 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
COVID-19
Efficacy and Safety of JT001 (VV116) Compared With Paxlovid
The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) Compared With Paxlovid for the Treatment of Coronavirus Disease 2019 (COVID-19) in Participants With Mild to Moderate COVID-19.
- Trial name
- NCT05341609
- Testing
- JT001, Paxlovid
- Where
- 7 sites in China
- Volunteers
- 822 people
- Sponsor
- Vigonvita Life Sciences
Mild to Moderate COVID-19
Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)
Clinical study of Humira (adalimumab) or placebo in subjects with mild-moderate COVID-19
- Trial name
- COMBAAT (NCT04705844)
- Testing
- Adalimumab
- Sponsor
- Alachua Government Services, Inc.
COVID-19
A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19
A Phase 3 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
- Trial name
- NCT05758519
- Testing
- QLS1128
- Where
- China
- Volunteers
- 1,220 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
COVID-19, SARS CoV 2 Infection
To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M
ProLectin M is an orally administered polysaccharide. Polysaccharides competitively bind to the N-terminal tail of human galectin-3 through a proline isomerization [10].
- Trial name
- NCT05733780
- Testing
- Prolectin-M
- Volunteers
- 40 people
- Sponsor
- Bioxytran Inc.
COVID-19
Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness
This is a Phase 1/2, randomized, double-blind, placebo-controlled, single-dose escalating-dose study in participants with mild to moderate COVID-19 illness.
- Trial name
- NCT05298813
- Testing
- IBIO123
- Where
- 11 sites in Brazil, South Africa
- Volunteers
- 162 people
- Sponsor
- Immune Biosolutions Inc
COVID19
Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19
This randomized, Phase I/II feasibility study will evaluate the safety and efficacy of the RD-X19 device in SARS-CoV-2 infected individuals with uncomplicated COVID-19.
- Trial name
- NCT04662671
- Testing
- RD-X19
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- EmitBio Inc.
Mild to Moderate COVID-19
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
This study is a double-blind,randomized,placebo-controlled study to evaluate the efficacy and safety of FB2001 for Inhalation in patients with mild to moderate Coronavirus Disease 2019(COVID-19).
- Trial name
- NCT05675072
- Testing
- FB2001
- Where
- China
- Volunteers
- 1,336 people
- Sponsor
- Frontier Biotechnologies Inc.
COVID-19
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
- Trial name
- NCT04486313
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 2 sites in United States
- Volunteers
- 935 people
- Sponsor
- Romark Laboratories L.C.
COVID-19
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
- Trial name
- SPRINT (NCT05616728)
- Testing
- EDP-235
- Where
- 23 sites in United States, Romania
- Volunteers
- 231 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Covid19
At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
This is an open-label, pragmatic, single-dose study using matched controls in participants with mild to moderate COVID-19. Participants will track for developing symptoms while at home and upon reporting of symptoms will test for…
- Trial name
- UNITED (NCT04656691)
- Testing
- bamlanivimab
- Where
- United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Daniel Griffin
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
COVID-19
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19
Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)
- Trial name
- NCT04501783
- Testing
- Favipiravir, Standard of care (SOC), standard concomitant therapy
- Where
- 10 sites in Russia
- Volunteers
- 168 people
- Sponsor
- R-Pharm
COVID-19
Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19
A randomized, 2-period crossover, single-center, open-label study for viral sample collection. After initiation of inhaled therapy with nebulizer or MDI, cascade impactors and surface samplers will be used to assess viral loads…
- Trial name
- NCT04681079
- Testing
- albuterol sulfate (MDI), albuterol sulfate (nebulizer)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Theravance Biopharma
Mild-to-Moderate COVID-19
A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function
This exploratory, open-label clinical study aims to explore the physiologic effects of KB109, a novel glycan, on adult patients with COVID-19 illness on gut microbiota structure and function in the outpatient setting.
- Trial name
- NCT04486482
- Testing
- KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- Kaleido Biosciences
COVID-19 Infection
Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection
A randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of WPV01 in patients with mild/moderate COVID-19 infection
- Trial name
- NCT05752175
- Testing
- WPV01
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
COVID-19
Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19
This Phase 2b study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD) and safety of sotrovimab in pediatric participants from birth to less than (<)18 years old with mild-to-moderate Coronavirus Disease-2019…
- Trial name
- COMET-PACE (NCT05124210)
- Testing
- Sotrovimab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline